Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.84 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.84 |
| ▸ | PLK4 | O00444 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | STK16 | O75716 | 2/20 | 0.84 |
| ▸ | RET | P07949 | 2/20 | 0.84 |
| ▸ | FLT3 | P36888 | 2/20 | 0.84 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.84 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.84 |
| ▸ | MST1R | Q04912 | 2/20 | 0.84 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.84 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.84 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.84 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.84 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.84 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.84 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.84 |
| ▸ | LATS1 | O95835 | 1/20 | 0.84 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29088767 | 0.99 | SYK (0.82) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL16858283 | 0.93 | SYK (0.82) | SYKPTK2PLK4AURKASTK16 | |
| Water SCHEMBL28356634 | 0.91 | SYK (0.85) | SYKPTK2PLK4AURKASTK16 | |
| Fostamatinib SCHEMBL29351337 | 0.91 | SYK (1.00) | SYKPTK2PLK4AURKASTK16 | |
| Fostamatinib SCHEMBL1201371 | 0.91 | SYK (1.00) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL4108129 | 0.91 | SYK (0.81) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL13451994 | 0.91 | SYK (0.91) | SYKPTK2PLK4AURKASTK16 | |
| Fostamatinib SCHEMBL22164570 | 0.91 | SYK (0.99) | SYKPTK2PLK4AURKASTK16 | |
| Fostamatinib SCHEMBL16820327 | 0.91 | SYK (0.99) | SYKPTK2PLK4AURKASTK16 | |
| SCHEMBL16682499 | 0.90 | SYK (0.80) | SYKPTK2PLK4AURKASTK16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234496-A | Improved treatment of advanced/metastatic cancers with checkpoint inhibitor resistance or drug resistance susceptibility | 海南先声再明医药股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117720516-A | Advantageous crystalline forms of selective BRD9 degrading agents | C4医药公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117562905-A | Maintenance of immune response during chemotherapy regimen | G1治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117530948-A | Maintenance of immune response during chemotherapy regimen | G1治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117440813-A | EGFR degrading agents for treating brain or CNS cancer metastasis | C4医药公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-116194438-A | Advantageous treatment of Ikaros or Aiolos mediated disorders | C4医药公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115806547-A | Selected compounds for targeted degradation of BRD9 | C4医药公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115768419-A | Improved methods and compositions for the treatment of prodrugs of chromanccalin | 奎拉里斯生物公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-108699024-B | Benzothienyl selective estrogen receptor down-regulator compounds | 伊利诺伊大学评议会 | 2022-03-11 | — | — | CN | disclosed |
| CN-108495628-B | Benzothienyl selective estrogen receptor down-modulators | 伊利诺伊大学评议会 | 2022-01-11 | — | — | CN | disclosed |
| CN-111837146-A | Excellent dosage regimen for G1T38 | G1治疗公司 | 2020-10-27 | — | — | CN | disclosed |